DAPAGLIFLOZIN 5MG EVAPHARMA 30 COATED TAB

DAPAGLIFLOZIN 5MG EVAPHARMA 30 COATED TAB

Description:

Dapagliflozin 5 mg Evapharma 30 coated tablets is an oral prescription antidiabetic medicine from EVA Pharma, belonging to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class. It is used as part of a comprehensive diabetes care plan to improve blood glucose control in adults with type 2 diabetes mellitus. By selectively inhibiting SGLT2 in the kidneys, dapagliflozin reduces renal glucose reabsorption and increases glucose excretion in urine, helping to lower fasting and postprandial blood sugar and support long-term glycemic control. It is typically used alongside diet, exercise, and sometimes other antidiabetic medications such as metformin or insulin.

Indications:

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• May be used as monotherapy in patients intolerant to metformin or in whom metformin is contraindicated (as per physician’s judgment).
• Combination therapy with other oral antidiabetic agents (e.g., metformin, sulfonylureas, DPP-4 inhibitors, thiazolidinediones) or insulin when these alone do not provide adequate glycemic control.
• Helps reduce elevated fasting and postprandial blood glucose levels and HbA1c in type 2 diabetes.
• May assist in modest weight reduction and blood pressure lowering as part of overall metabolic management (clinical effect varies by patient).
• Not indicated for type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Active Ingredients / Key Components:

• Dapagliflozin – 5 mg per film-coated tablet.
• Excipients: film-coating and tablet core excipients (exact excipient list and concentrations , please check the product leaflet or the manufacturer’s official website; please refer to the official package leaflet).

Dosage & Administration / How to Use:

• Usual adult dose: 5 mg dapagliflozin orally once daily, as directed by the prescribing physician.
• Tablets should be swallowed whole with water; do not crush, chew, or split unless advised by a healthcare professional.
• Can be taken with or without food, preferably at the same time each day to support consistent blood levels and adherence.
• In some patients, the dose may be adjusted or combined with other antidiabetic medications according to blood glucose response and tolerability, under medical supervision.
• Renal function, volume status, and risk factors for ketoacidosis should be assessed before initiation and periodically during treatment.
• If a dose is missed, take it as soon as remembered on the same day; if it is almost time for the next dose, skip the missed dose and resume the regular schedule. Do not double the dose.
• Use only under medical supervision and as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring.

Clinical Benefits:

• Improves glycemic control in adults with type 2 diabetes by promoting urinary glucose excretion through selective SGLT2 inhibition.
• Helps lower HbA1c levels when used alone or in combination with other antidiabetic agents, supporting long-term diabetes management.
• Reduces fasting and postprandial blood glucose levels, contributing to better daily blood sugar stability.
• May contribute to modest weight loss due to caloric loss via glycosuria, as part of an overall lifestyle and treatment plan.
• Can provide a low risk of hypoglycemia when used as monotherapy or with agents that do not themselves cause hypoglycemia (risk increases when combined with insulin or sulfonylureas).

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to dapagliflozin or any component of the formulation.
• Not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis due to increased risk of ketoacidosis.
• Use with caution in patients with moderate to severe renal impairment; efficacy is reduced and risk of adverse effects may increase. In some levels of renal impairment, use may be contraindicated according to official guidelines—follow physician and local labeling.
• May increase risk of volume depletion, hypotension, and dehydration, especially in elderly patients, those on diuretics, or with low blood pressure. Ensure adequate fluid intake.
• Increased risk of genital mycotic infections and urinary tract infections; patients should maintain good genital hygiene and seek medical advice if symptoms occur.
• Reports of euglycemic diabetic ketoacidosis have occurred with SGLT2 inhibitors; monitor for symptoms such as nausea, vomiting, abdominal pain, difficulty breathing, confusion, or unusual fatigue, even if blood glucose is not markedly elevated.
• Use with caution in patients with a history of recurrent urinary tract infections, genital infections, or conditions predisposing to ketoacidosis (e.g., low carbohydrate intake, acute illness, reduced insulin dose).
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding; safety data in pregnancy and lactation are limited and use is generally not recommended unless clearly needed.
• Consult your doctor before use if you have liver disease, kidney disease, cardiovascular disease, low blood pressure, or are taking diuretics, insulin, or other antidiabetic medications.
• Monitor blood glucose regularly and follow your doctor’s instructions regarding dose adjustments of concomitant diabetes medications to reduce risk of hypoglycemia.
• Not intended to diagnose, treat, cure, or prevent any disease without medical supervision; this is a prescription medicine and must be used only as directed by a healthcare professional.
• Keep out of reach of children.

Side Effects:

• Common side effects: increased urination, genital fungal infections (e.g., vulvovaginal candidiasis, balanitis), urinary tract infections, thirst, mild dehydration, and dyslipidemia (slight increases in LDL cholesterol in some patients).
• Other possible side effects: dizziness or lightheadedness (especially on standing) due to low blood pressure, rash, pruritus, or allergic reactions.
• Serious but less common side effects: ketoacidosis (including euglycemic ketoacidosis), severe urinary tract infections (e.g., pyelonephritis), urosepsis, significant volume depletion, and rare cases of Fournier’s gangrene (necrotizing fasciitis of the perineum).
• Seek immediate medical attention if you experience symptoms of severe infection, difficulty breathing, persistent nausea or vomiting, severe abdominal pain, confusion, high fever, or signs of allergic reaction such as swelling of the face, lips, tongue, or throat.
• Report any unusual or bothersome symptoms to your doctor or pharmacist promptly.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not use after the expiry date stated on the package. Store at or below the temperature specified on the official pack (exact temperature range is not available in the provided information; refer to the product carton or leaflet).

Specifications:

• Form: Film-coated tablets.
• Strength: 5 mg dapagliflozin per tablet.
• Pack size: 30 film-coated tablets per pack.
• Route of administration: Oral.
• Intended use: Prescription antidiabetic medicine for adults with type 2 diabetes mellitus, as directed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.